ProKidney Corp. Prepares for Key Industry Conferences
ProKidney Corp. (Nasdaq: PROK), a leader in cellular therapeutics specifically targeting chronic kidney disease (CKD), is gearing up to take part in two significant healthcare conferences. This participation illustrates the company's commitment to advancing strategies and nurturing investor relationships in the healthcare sector.
Highlights of the Upcoming Conferences
The first event is the acclaimed Guggenheim Healthcare Innovation Conference, scheduled in Boston. This conference promises to be an excellent opportunity for ProKidney’s management team to engage in dynamic conversations about current trends and innovations in healthcare.
Prior to participating in the conference, ProKidney will hold a fireside chat on Wednesday, November 12, where insights on the company's ongoing projects and therapeutic advancements will be shared. Doors will open at 10:00 AM ET, and all interested parties can access the live webcast via ProKidney’s website.
Understanding the Fireside Chat
This fireside chat provides a platform for ProKidney’s leadership to discuss pivotal topics surrounding the fight against CKD. The live webcast will be easily accessible through the 'Events' section located in the Investor Relations tab on the company’s site.
Networking Opportunities at Jefferies Global Healthcare Conference
Following the Guggenheim event, ProKidney will also attend the Jefferies Global Healthcare Conference in London, occurring from November 17 to November 20. This conference allows for one-on-one meetings and deeper discussions regarding the company's pioneering work in cellular therapy designed to treat CKD.
One-on-One Meetings Invitation
Investors and stakeholders interested in meeting with ProKidney’s team can arrange one-on-one sessions through their banking representatives. These meetings will provide an intimate setting for discussing specific interests and learning more about ProKidney's groundbreaking initiatives.
The Science Behind ProKidney
Founded on a decade of solid research, ProKidney is at the forefront of developing therapies that could transform how CKD is managed. The company’s flagship product, rilparencel, represents a significant innovation in cellular therapy. This proprietary solution is a pioneering autologous therapy possessing regenerative medicine advanced therapy designation. It is presently undergoing evaluation in the Phase 3 REGEN-006 study, focused on preserving renal function in patients suffering from advanced CKD and accompanying type 2 diabetes.
Impacts of Rilparencel Treatment
Rilparencel aims to address a pressing need for more effective and long-lasting solutions for CKD patients. With the prevalence of chronic kidney disease on the rise, developments like these are pivotal for improving patient outcomes and advancing the field of renal health.
Contact Information for ProKidney
For inquiries, ProKidney encourages interested parties to reach out to their contacts. Ethan Holdaway, a representative of ProKidney, is available to assist with inquiries at Ethan.Holdaway@prokidney.com. Furthermore, media inquiries can be directed to their PR contact, Audra Friis, at audrafriis@sambrown.com.
Frequently Asked Questions
What are the key conferences ProKidney will attend?
ProKidney will be participating in the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference.
How can I access the fireside chat?
The fireside chat will be available live on ProKidney's website under the ‘Events’ section in the Investor Relations tab.
What is rilparencel?
Rilparencel is ProKidney’s lead product candidate, an innovative autologous cellular therapy aimed at preserving kidney function in patients with advanced chronic kidney disease.
Who can I contact for more information about ProKidney?
You can contact Ethan Holdaway at Ethan.Holdaway@prokidney.com for inquiries regarding ProKidney.
When are the conferences taking place?
The Guggenheim Healthcare Innovation Conference is on November 12, and the Jefferies Global Healthcare Conference runs from November 17-20.
